BONADUZ, Switzerland — December 16, 2025 — Hamilton Company announced the launch of GlucoSense, a first-of-its-kind, reusable, real-time, in situ glucose sensor designed specifically for mammalian cell culture bioreactors. The new technology enables continuous glucose monitoring directly inside bioreactors, addressing a long-standing analytical gap in upstream bioprocessing. By delivering real-time nutrient data comparable in simplicity to pH and dissolved oxygen measurements, GlucoSense is positioned to fundamentally improve biopharmaceutical process control, development efficiency, and manufacturing robustness.
Science Significance
From a scientific perspective, GlucoSense represents a major advancement in bioprocess analytics and cell culture monitoring. Glucose is a critical driver of cell metabolism, lactate accumulation, cell viability, and product quality attributes such as N-linked glycosylation, yet it has traditionally been monitored using intermittent offline sampling. GlucoSense eliminates this limitation through continuous, in situ measurement using mid-infrared ATR spectroscopy, tuned specifically to glucose absorption signatures. The sensor’s fiber-optic-free design, coupled with a semi-permeable membrane that prevents fouling of the ATR element, enables stable, drift-resistant performance over extended cultivation runs, even in high-density CHO perfusion processes.
Regulatory Significance
Regulatory expectations for modern biologics manufacturing increasingly emphasize process understanding, real-time monitoring, and data integrity, consistent with Quality by Design (QbD) and Process Analytical Technology (PAT) principles. GlucoSense aligns closely with these expectations by enabling continuous monitoring of a critical process parameter without reliance on complex chemometric models. Integrated Arc intelligent sensor technology stores calibration constants, diagnostics, and quality indicators directly within the sensor head, supporting GMP-ready documentation and auditability. The planned development of a SIP- and steam-compatible version further positions GlucoSense for use in clinical and commercial GMP environments.
Business Significance
Advertisement
Commercially, GlucoSense establishes Hamilton as a category leader in next-generation bioprocess sensors. Initially available for wetted autoclave workflows in glass and benchtop bioreactors, the product addresses the needs of R&D and early process development teams, while Hamilton’s roadmap extends its applicability through to large-scale steel bioreactors by 2026. By reducing reliance on labor-intensive sampling, consumables, and external analyzers, GlucoSense offers manufacturers a pathway to lower operational complexity, improve scalability, and accelerate development timelines, strengthening Hamilton’s value proposition across the biopharma lifecycle.
Patients’ Significance
Although GlucoSense is not a patient-facing technology, its impact ultimately reaches patients through improved biologic drug quality and supply reliability. More precise glucose control supports consistent product critical quality attributes, reducing batch variability and the risk of manufacturing deviations. For patients relying on monoclonal antibodies, recombinant proteins, or cell-based therapies, enhanced process control translates into safer, more reliable, and more consistently available medicines, reinforcing trust in advanced biologic therapies.
Policy Significance
At the policy level, the introduction of GlucoSense supports global regulatory and industry initiatives promoting digitalization, continuous manufacturing, and advanced analytics in pharmaceutical production. Regulatory agencies increasingly encourage the adoption of real-time monitoring tools to strengthen process robustness and supply chain resilience. By closing one of the last major analytical blind spots in upstream processing, GlucoSense contributes to policy goals focused on modernizing biomanufacturing infrastructure and improving long-term drug supply security.
With the launch of GlucoSense, Hamilton has introduced a transformative tool that redefines how glucose is monitored in mammalian cell culture. By combining robust sensor engineering, real-time analytics, and GMP-aligned digital integration, the technology enables biopharmaceutical manufacturers to move closer to truly data-driven, adaptive bioprocessing. For the cGxP.wire audience, GlucoSense exemplifies how innovative process technologies underpin compliance, efficiency, and product quality across the biologics development and manufacturing continuum.
Source: Hamilton Company press release
